CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 25 enrolled
Drug / intervention
Terlipressin +1 moredrug
Likely dose
Terlipressin 4 µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02059460
NCT02059460Phase 4Completed
CompareCT.gov

Perioperative Evaluation of Terlipressin Infusion During Living Donor Liver Transplantation on Incidence of Acute Kidney

National Liver Institute, Egypt·interventional·Posted Feb 11, 2014·Updated Dec 15, 2016

In Brief

A Phase 4 clinical trial evaluating Terlipressin and placebo for Acute Kidney Injury and 3 related conditions. Completed, enrolled 25 participants across 1 site.

Detailed Summary

To study the impact of intra and post-operative Terlipressin infusion on the occurrence of acute kidney injury after LDLT To investigate perioperative Neutrophil Gelatinase Associated Lipocalin (NGAL) changes and study the effect of Terlipressin on NGAL blood levels

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Kidney Injury, Liver Transplantation, Terlipressin, NGAL
CountriesEgypt
CollaboratorsDr. Mohamed Helmi Ibrahim Afifi, Dr. Khaled Ahmed Yassen, Dr. Khalid Mousa Abouelenain, Dr. Mohamed Abdelrauf kandil, Dr. Ayman Alsebaey Qotb Alghoraieb.

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedFeb 11, 2014
Enrollment StartMay 1, 2013
Primary CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 12.4 years ago

Interventions

Terlipressindrug

Terlipressin (Glypressin®) will be started by continuous infusion at a dose of 1-4 µg/kg/h till day 4 postoperatively

placebodrug